Selected research
Industry Research
Injectable HIV Medication Industry Research Report 2026
Market perspective
The global Injectable HIV Medication market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Injectable HIV Medication is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Injectable HIV Medication is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Injectable HIV Medication is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Injectable HIV Medication include Theratechnologies, ViiV Healthcare, Gilead Sciences and Janssen Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Injectable HIV Medication market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Injectable HIV Medication Market by Company
Theratechnologies
ViiV Healthcare
Gilead Sciences
Janssen Pharmaceuticals
Injectable HIV Medication Segment by Type
Integrase Inhibitors
Capsid Inhibitors
NNRTIs
Monoclonal Antibodies
Other
Injectable HIV Medication Segment by Application
Pre-Exposure Prophylaxis
HIV Treatment
Injectable HIV Medication Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Injectable HIV Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Injectable HIV Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Injectable HIV Medication.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Injectable HIV Medication manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Injectable HIV Medication by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Injectable HIV Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Integrase Inhibitors
- Capsid Inhibitors
- NNRTIs
- Monoclonal Antibodies
- Other
Applications
- Pre-Exposure Prophylaxis
- HIV Treatment
Companies covered
- Theratechnologies
- ViiV Healthcare
- Gilead Sciences
- Janssen Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Injectable HIV Medication Market Size (2021-2032)
- 2.2.2 Global Injectable HIV Medication Sales (2021-2032)
- 2.2.3 Global Injectable HIV Medication Market Average Price (2021-2032)
- 2.3 Injectable HIV Medication by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Integrase Inhibitors
- 2.3.3 Capsid Inhibitors
- 2.3.4 NNRTIs
- 2.3.5 Monoclonal Antibodies
- 2.3.6 Other
- 2.4 Injectable HIV Medication by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Pre-Exposure Prophylaxis
- 2.4.3 HIV Treatment
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Injectable HIV Medication Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Injectable HIV Medication Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Injectable HIV Medication Revenue of Manufacturers (2021-2026)
- 3.4 Global Injectable HIV Medication Average Price by Manufacturers (2021-2026)
- 3.5 Global Injectable HIV Medication Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Injectable HIV Medication, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Injectable HIV Medication, Product Type & Application
- 3.8 Global Manufacturers of Injectable HIV Medication, Established Date
- 3.9 Global Injectable HIV Medication Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Theratechnologies
- 4.1.1 Theratechnologies Company Information
- 4.1.2 Theratechnologies Business Overview
- 4.1.3 Theratechnologies Injectable HIV Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Theratechnologies Injectable HIV Medication Product Portfolio
- 4.1.5 Theratechnologies Recent Developments
- 4.2 ViiV Healthcare
- 4.2.1 ViiV Healthcare Company Information
- 4.2.2 ViiV Healthcare Business Overview
- 4.2.3 ViiV Healthcare Injectable HIV Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 ViiV Healthcare Injectable HIV Medication Product Portfolio
- 4.2.5 ViiV Healthcare Recent Developments
- 4.3 Gilead Sciences
- 4.3.1 Gilead Sciences Company Information
- 4.3.2 Gilead Sciences Business Overview
- 4.3.3 Gilead Sciences Injectable HIV Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Gilead Sciences Injectable HIV Medication Product Portfolio
- 4.3.5 Gilead Sciences Recent Developments
- 4.4 Janssen Pharmaceuticals
- 4.4.1 Janssen Pharmaceuticals Company Information
- 4.4.2 Janssen Pharmaceuticals Business Overview
- 4.4.3 Janssen Pharmaceuticals Injectable HIV Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Janssen Pharmaceuticals Injectable HIV Medication Product Portfolio
- 4.4.5 Janssen Pharmaceuticals Recent Developments
5 Global Injectable HIV Medication Market Scenario by Region
- 5.1 Global Injectable HIV Medication Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Injectable HIV Medication Sales by Region: 2021-2032
- 5.2.1 Global Injectable HIV Medication Sales by Region: 2021-2026
- 5.2.2 Global Injectable HIV Medication Sales by Region: 2027-2032
- 5.3 Global Injectable HIV Medication Revenue by Region: 2021-2032
- 5.3.1 Global Injectable HIV Medication Revenue by Region: 2021-2026
- 5.3.2 Global Injectable HIV Medication Revenue by Region: 2027-2032
- 5.4 North America Injectable HIV Medication Market Facts & Figures by Country
- 5.4.1 North America Injectable HIV Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Injectable HIV Medication Sales by Country (2021-2032)
- 5.4.3 North America Injectable HIV Medication Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Injectable HIV Medication Market Facts & Figures by Country
- 5.5.1 Europe Injectable HIV Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Injectable HIV Medication Sales by Country (2021-2032)
- 5.5.3 Europe Injectable HIV Medication Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Injectable HIV Medication Market Facts & Figures by Country
- 5.6.1 Asia Pacific Injectable HIV Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Injectable HIV Medication Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Injectable HIV Medication Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Injectable HIV Medication Market Facts & Figures by Country
- 5.7.1 South America Injectable HIV Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Injectable HIV Medication Sales by Country (2021-2032)
- 5.7.3 South America Injectable HIV Medication Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Injectable HIV Medication Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Injectable HIV Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Injectable HIV Medication Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Injectable HIV Medication Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Injectable HIV Medication Sales by Type (2021-2032)
- 6.1.1 Global Injectable HIV Medication Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Injectable HIV Medication Sales Market Share by Type (2021-2032)
- 6.2 Global Injectable HIV Medication Revenue by Type (2021-2032)
- 6.2.1 Global Injectable HIV Medication Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Injectable HIV Medication Revenue Market Share by Type (2021-2032)
- 6.3 Global Injectable HIV Medication Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Injectable HIV Medication Sales by Application (2021-2032)
- 7.1.1 Global Injectable HIV Medication Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Injectable HIV Medication Sales Market Share by Application (2021-2032)
- 7.2 Global Injectable HIV Medication Revenue by Application (2021-2032)
- 7.2.1 Global Injectable HIV Medication Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Injectable HIV Medication Revenue Market Share by Application (2021-2032)
- 7.3 Global Injectable HIV Medication Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Injectable HIV Medication Value Chain Analysis
- 8.1.1 Injectable HIV Medication Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Injectable HIV Medication Production Mode & Process
- 8.2 Injectable HIV Medication Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Injectable HIV Medication Distributors
- 8.2.3 Injectable HIV Medication Customers
9 Global Injectable HIV Medication Analyzing Market Dynamics
- 9.1 Injectable HIV Medication Industry Trends
- 9.2 Injectable HIV Medication Industry Drivers
- 9.3 Injectable HIV Medication Industry Opportunities and Challenges
- 9.4 Injectable HIV Medication Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst